<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04624035</url>
  </required_header>
  <id_info>
    <org_study_id>ICL vs IPCL</org_study_id>
    <nct_id>NCT04624035</nct_id>
  </id_info>
  <brief_title>Implantable Phakic Lens (IPCL) VS Implantable Collamer Lens</brief_title>
  <official_title>Comparison Between Implantable Phakic Intraocular Lens and Implantable Collamer Lens in Treatment of Myopia in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phakic intraocular lenses (pIOL) of different designs and materials have been used&#xD;
      effectively instead of corneal refractive surgery in certain situations. The pIOL exhibits a&#xD;
      number of advantages over corneal techniques as it is suitable for high myopes, with lower&#xD;
      production of aberrations, and superior contrast sensitivity. Keeping the accommodation is&#xD;
      its definite lead over refractive lens exchange. The Visian implantable collamer lens (ICL;&#xD;
      Staar Surgical, Monrovia, CA), a posterior chamber pIOL, has been stated to be useful for the&#xD;
      correction of high myopia. Nevertheless, as an intraocular procedure, it is associated with a&#xD;
      risk of complications as probable injury to anterior segment, retinal detachment and&#xD;
      endophthalmitis.&#xD;
&#xD;
      The Implantable Phakic Contact Lens (IPCL V2, Caregroup Sight Solutions, India) has been&#xD;
      developed as an alternative for the ICL, at a noticeable financial advantage. Furthermore,&#xD;
      the highestmyopic correction which is instantly accessible with ICL is -18.0 D. Meanwhile,&#xD;
      IPCL can provide correction higher degrees up to -30.0 D.&#xD;
&#xD;
      Former researches have been made to assess the safety and efficiency of ICL implantation, to&#xD;
      evaluate various devices for anterior segment imaging postoperatively and to identify changes&#xD;
      in anterior segment after surgery. A recent study determined the safety of the IPCL over a&#xD;
      minimum follow-up period of one year. In this work the investigators aimed to compare the&#xD;
      refractive results and the adverse effects of the IPCL and the ICL in treatment of myopia in&#xD;
      adults.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 10, 2020</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Refractive outcome</measure>
    <time_frame>12 months</time_frame>
    <description>Postoperative refractive error measured in spherical equivalent</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual outcome</measure>
    <time_frame>12 months</time_frame>
    <description>Uncorrected distance and near vision using Snellen's chart and using decimal fractions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse reactions</measure>
    <time_frame>12 months</time_frame>
    <description>adverse reactions will be recorded including intraocular inflammation, corneal endothelial changes and lens opactification</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Myopia</condition>
  <arm_group>
    <arm_group_label>Implantable Collamer Lens (ICL, V4c with central hole) in treatment of myopia in adults.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Implantation of ICL (V4c with central hole) for treatment of myopia in adults using peribulbar anesthesia. Thirty minutes before surgery, cycloplegic and phenylephrine eye drops were applied. Five minutes before surgery, povidone-iodine 5% was applied. The anterior chamber was filled with sodium hyaluronate 1%, which was completely removed at the end of the surgery. The lens was inserted using the ICL injector. Tobramycin and dexamethasone 0.1% eye drops were used four times a day for 10 days, after which diclofenac sodium eye drops were started four times a day for 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acrylic Implantable Intraocular Lens (IPCL, V2) in treatment of myopia in adults</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Implantation of IPCL for treatment of Myopia in adults using peribulbar anesthesia. Thirty minutes before surgery, cycloplegic and phenylephrine eye drops were applied. Five minutes before surgery, povidone-iodine 5% was applied. The anterior chamber was filled with sodium hyaluronate 1%, which was completely removed at the end of the surgery. The lens was inserted using the IPCL injector. Tobramycin and dexamethasone 0.1% eye drops were used four times a day for 10 days, after which diclofenac sodium eye drops were started four times a day for 2 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Implantable Collamer Lens (ICL) in treatment of myopia in adults.</intervention_name>
    <description>ICL Group: After mydriatic eye drops and topical anesthesia instillation, a 3-mm temporal corneal incision was done. Viscoelastic material was injected in the anterior chamber (AC). An injector cartridge (STAAR Surgical) was used to insert the ICL V4c model with central hole). The four footplates of the ICL were positioned on the ciliary sulcus at the 180° axis. Viscoelastic material was entirely taken away.</description>
    <arm_group_label>Implantable Collamer Lens (ICL, V4c with central hole) in treatment of myopia in adults.</arm_group_label>
    <other_name>All drugs used were mentioned in the arm description</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Implantable Intraocular Lens (IPCL) in treatment of myopia in adults.</intervention_name>
    <description>IPCL Group: Topical anesthetic and mydriatic agents were instilled before surgery. Using peripulbar anaesthesia, the IPCL (V2 model with central hole) was implanted into the AC through a 3 mm clear corneal incision after viscoelastic material injection. The footplates were subsequently tucked behind the iris, followed by a thorough viscoelastic removal.</description>
    <arm_group_label>Acrylic Implantable Intraocular Lens (IPCL, V2) in treatment of myopia in adults</arm_group_label>
    <other_name>All drugs used were mentioned in the arm description</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  myopia of more than 6 diopter&#xD;
&#xD;
          -  central anterior chamber depth more than 2.8 mm&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  unstable refraction&#xD;
&#xD;
          -  any other ocular disease&#xD;
&#xD;
          -  any systemic disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mahmoud F Rateb, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assiut University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mahmoud F Rateb, MD</last_name>
    <phone>‭+20 100 8348480‬</phone>
    <email>rateb@aun.edu.eg</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tiba eye center</name>
      <address>
        <city>Asyut</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mahmoud Rateb, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Al Masa eye center</name>
      <address>
        <city>Banhā</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamed ElMohamady, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Stulting RD, John ME, Maloney RK, Assil KK, Arrowsmith PN, Thompson VM; U.S. Verisyse Study Group. Three-year results of Artisan/Verisyse phakic intraocular lens implantation. Results of the United States Food And Drug Administration clinical trial. Ophthalmology. 2008 Mar;115(3):464-472.e1. Epub 2007 Nov 26.</citation>
    <PMID>18031820</PMID>
  </reference>
  <reference>
    <citation>Kamiya K, Igarashi A, Shimizu K, Matsumura K, Komatsu M. Visual performance after posterior chamber phakic intraocular lens implantation and wavefront-guided laser in situ keratomileusis for low to moderate myopia. Am J Ophthalmol. 2012 Jun;153(6):1178-86.e1. doi: 10.1016/j.ajo.2011.12.005. Epub 2012 Feb 23.</citation>
    <PMID>22365084</PMID>
  </reference>
  <reference>
    <citation>Sanders D, Vukich JA. Comparison of implantable collamer lens (ICL) and laser-assisted in situ keratomileusis (LASIK) for low myopia. Cornea. 2006 Dec;25(10):1139-46.</citation>
    <PMID>17172886</PMID>
  </reference>
  <reference>
    <citation>Igarashi A, Kamiya K, Shimizu K, Komatsu M. Visual performance after implantable collamer lens implantation and wavefront-guided laser in situ keratomileusis for high myopia. Am J Ophthalmol. 2009 Jul;148(1):164-70.e1. doi: 10.1016/j.ajo.2009.02.001. Epub 2009 Apr 17.</citation>
    <PMID>19375059</PMID>
  </reference>
  <reference>
    <citation>Pineda-Fernández A, Jaramillo J, Vargas J, Jaramillo M, Jaramillo J, Galíndez A. Phakic posterior chamber intraocular lens for high myopia. J Cataract Refract Surg. 2004 Nov;30(11):2277-83.</citation>
    <PMID>15519075</PMID>
  </reference>
  <reference>
    <citation>Elmohamady MN, Abdelghaffar W. Anterior Chamber Changes After Implantable Collamer Lens Implantation in High Myopia Using Pentacam: A Prospective Study. Ophthalmol Ther. 2017 Dec;6(2):343-349. doi: 10.1007/s40123-017-0109-3. Epub 2017 Sep 20.</citation>
    <PMID>28933042</PMID>
  </reference>
  <reference>
    <citation>Fernandes P, González-Méijome JM, Madrid-Costa D, Ferrer-Blasco T, Jorge J, Montés-Micó R. Implantable collamer posterior chamber intraocular lenses: a review of potential complications. J Refract Surg. 2011 Oct;27(10):765-76. doi: 10.3928/1081597X-20110617-01. Epub 2011 Jun 30. Review.</citation>
    <PMID>21710954</PMID>
  </reference>
  <reference>
    <citation>Sachdev G, Ramamurthy D. Long-term safety of posterior chamber implantable phakic contact lens for the correction of myopia. Clin Ophthalmol. 2019 Jan 7;13:137-142. doi: 10.2147/OPTH.S185304. eCollection 2019.</citation>
    <PMID>30662257</PMID>
  </reference>
  <reference>
    <citation>Zhang J, Luo HH, Zhuang J, Yu KM. Comparison of anterior section parameters using anterior segment optical coherence tomography and ultrasound biomicroscopy in myopic patients after ICL implantation. Int J Ophthalmol. 2016 Jan 18;9(1):58-62. doi: 10.18240/ijo.2016.01.10. eCollection 2016.</citation>
    <PMID>26949611</PMID>
  </reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 20, 2020</study_first_submitted>
  <study_first_submitted_qc>November 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2020</study_first_posted>
  <last_update_submitted>November 5, 2020</last_update_submitted>
  <last_update_submitted_qc>November 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Mahmoud F. Rateb</investigator_full_name>
    <investigator_title>Associate professor of ophthalmology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myopia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All of the individual participant data that underline the results of this trial will be available once completion of the study after de-identification.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>beginning 9 month and ending 36 months after trial publication</ipd_time_frame>
    <ipd_access_criteria>for individual participant data meta-analysis</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

